Navigation Links
Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
Date:2/17/2010

GREENSBORO, N.C., Feb. 17 /PRNewswire/ -- Stretch marks can make even the most beautiful women feel insecure and self-conscious. Approximately 90% of pregnant women and 70% of adolescent females have stretch marks, and they also commonly occur in people who have lost weight within a brief time period. Although they pose no health risks, stretch marks can cause negative body image issues for women of all shapes and sizes. With new Mederma® Stretch Marks Therapy women now have an effective, clinically proven option to improve the appearance of their stretch marks.

From the makers of #1 doctor-recommended brand for scars for over a decade, Mederma® Stretch Marks Therapy is a patented formula that combines a unique blend of ingredients, including the proprietary botanical extract Cepalin®, hyaluronic acid and centella asiatica leaf extract. This advanced formula is dermatologist tested and clinically proven to reduce discoloration, improve texture and enhance skin's softness, with noticeable improvement in about 4 weeks, and optimum improvement in 12 weeks when used twice daily.

"Stretch marks are very common and occur when the skin is stretched beyond a certain degree, such as during pregnancy or in times of weight increase when the connective tissue can be disrupted and show unattractive red marks on the skin's surface," says Zoe Diana Draelos, MD, a clinical and research dermatologist based in High Point, North Carolina, with a special interest in problems associated with skin, hair and nails. "In the clinical trial, 80% of women noted visible improvement in their stretch marks compared to non treatment, with a trend toward improved elasticity."

"Stretch marks can be a nagging reminder to new moms who have worked hard to lose their baby weight," says Victoria Pericon of Mom Blog Savvymommy.com. "An effective product that could help to improve the appearance of their stretch marks would provide a real confidence boost for these women," she added.

Mederma® Stretch Marks Therapy is effective for all the areas of the body where stretch marks occur, including the arms, abdomen and buttocks. For best results, Mederma® Stretch Marks Therapy should be used as directed twice a day for 12 weeks.

Mederma® Stretch Marks Therapy is sold in a 5.29-oz tube and retails for $39.99. It is now available at CVS, Walgreens and in other drugstores nationwide.

About Mederma®

The Mederma® family of products, including Mederma® Gel, Mederma® Cream plus SPF 30, and Mederma® for Kids, has a long tradition of efficacy. The #1 doctor- and pharmacist-recommended brand for scars, Mederma® helps reduce the appearance of scars resulting from surgery, injury, burns, and acne, making them softer, smoother, and less noticeable. To learn more, visit www.mederma.com.

About Merz Pharmaceuticals

Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma®.

With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

SOURCE Merz Pharmaceuticals, LLC

RELATED LINKS
http://www.mederma.com

'/>"/>

SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... Piramal Enterprises Limited, gibt die Ernennung von ... PPS bietet seinen globalen Pharmazeutikkunden eine einmalige ... eine wichtige Rolle für das erfolgreiche Wachstum ... kaufmännischer Leiter wird Herr Needleman dafür verantwortlich ...
(Date:3/23/2017)... March 23, 2017 Pre-market today, Stock-Callers.com ... PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: HZNP), and Evoke ... stocks are part of the Healthcare sector, which was slightly ... 2017, with the NYSE Health Care Index adding about 0.1% ... S&P 500 also were up nearly 0.1% as a group. ...
(Date:3/23/2017)... 23, 2017 AbbVie, a global biopharmaceutical company, ... Julianne Hough is helping to raise awareness ... Know about ME in EndoMEtriosis . "   The ... to learn about and understand endometriosis, a disease affecting ... to address their symptoms with a healthcare professional.  Despite ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare ... Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, ... for all medical chart types with a comprehensive set of features including built-in ...
(Date:3/23/2017)... ... ... Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded Church. ... author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording artist, ... husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering in ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... the existence of God. “A Respectful Response To Atheist Manifesto” is the creation ... married to his wife, Nancy, for sixty years. He holds graduate degrees from ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider ... protein expression in circulating tumor cells using microfluidic western blotting” in Nature Communications ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
Breaking Medicine News(10 mins):